QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
QR-Bromocriptine as an add-on treatment to insulin and metformin in the management of type 2
diabetes will result in improved glycemic control, reduced exogenous insulin requirement,
increased lean fat mass and improved pancreatic beta-cell function.